What a Year of Gaucher Disease Treatment Costs, From Cerezyme Infusions to the Venglustat Pill Due for an FDA Decision November 25th

About 50,000 human placentas a year, some 10 to 12 metric tons, went into each patient's supply of Ceredase, the first treatment for Gaucher disease, according to a history of the drug written by 2 Gaucher physicians (Deegan and Cox, 2012). The enzyme is now grown in factories, yet a year of it still costs Medicare hundreds of thousands of dollars, and the bill rises with every kilogram a patient weighs. This guide works out that cost for each Gaucher medicine from Medicare's own 2024 spending figures, answers the questions families search for and rarely find answered, and explains the FDA decision due November 25th on venglustat, a once-daily pill that Sanofi says would be the first US treatment for the neurological symptoms of type 3 Gaucher disease.

Gaucher Disease Treatment in 2026, 5 Approved Medicines and 1 Pill Under FDA Review

Gaucher disease is inherited. People with it lack enough of an enzyme called glucocerebrosidase, so a fatty substance builds up inside scavenger cells called macrophages in the spleen, liver, bone marrow and lungs, which leads to a swollen spleen and liver, low blood counts and bone damage. Type 1, the most common form, spares the brain. Type 2 brings rapid neurological decline, and type 3, the chronic form, adds slower neurological problems such as poor balance and coordination and trouble with thinking (Sanofi, 2026). Studies of gene frequency suggest about 20,000 people in the United States carry 2 disease-causing copies of the GBA1 gene, two-thirds of them of Ashkenazi Jewish descent, though not all of them develop symptoms (Deegan and Cox, 2012).

At Medicare's 2024 average of about $4.30 per unit, a year of Cerezyme at the label's top dose of 60 units per kilogram every 2 weeks comes to about $6,700 for every kilogram a person weighs, roughly $470,000 for a 70 kg (154 lb) adult and $168,000 for a 25 kg (55 lb) child. The enzymes are sold by the unit and dosed by the kilogram, so a bigger body needs more vials at every infusion. Trial Friend's figures multiply the average Medicare Part B spending per unit that CMS reports for 2024 (Cerezyme $43.02 per 10 units, VPRIV $359.16 per 100 units, Elelyso $42.69 per 10 units) by the dose on each label and 26 infusions a year, checked October 16, 2026.

Medicare's real bill per patient came in lower than that math. In 2024 Medicare spent an average of $316,023 for each of the 140 Cerezyme patients in CMS's Part B data, $305,343 for each of 107 VPRIV patients and $419,589 for each of 12 Elelyso patients (CMS, 2024). Divided by patient count, the 10.3 million Cerezyme units Medicare paid for come to about 73,500 units a person, a full year at the top dose for someone weighing about 47 kg. Many patients take lower maintenance doses and some were covered for only part of the year, and CMS's figures do not separate the two.

Dose has driven price since the first enzyme. Ceredase was priced per unit of enzyme activity, so, as Deegan and Cox put it, the cost question became partly a question of dose. Some physicians followed the 60 units per kilogram every other week used in the first trial, while others gave 2 to 3 units per kilogram 2 or 3 times a week, and the argument between the camps was often heated (Deegan and Cox, 2012). Cerezyme's current label spans both ends, from 2.5 units per kilogram 3 times a week to 60 units per kilogram every 2 weeks, adjusted to severity and treatment goals.

What Gaucher patients pay out of pocket

Medicare Part B covers enzyme infusions and leaves a 20% coinsurance unless a supplemental plan pays it, while the pills fall under Part D, where 2026 out-of-pocket spending stops at $2,100 for the year (CMS, 2025). Commercially insured patients can apply to each maker's copay program: Sanofi's CareConnect for Cerezyme and Cerdelga, Takeda Patient Support for VPRIV, and Pfizer's Gaucher Personal Support for Elelyso. Copay cards exclude Medicare and Medicaid, though Pfizer's patient assistance program can provide Elelyso free to qualifying uninsured or government-insured patients. Trial Friend's help paying page lists each program with what it covers.

Is There a Generic Cerezyme? Why VPRIV and Elelyso Are Not Copies

No generic or biosimilar version of Cerezyme is sold in the United States. Enzymes are biologics, which can only be copied through the FDA's biosimilar pathway, and the FDA's list of approved biosimilars, current as of October 5, 2026, has none for imiglucerase. VPRIV and Elelyso are separate enzymes, each approved on its own trials: VPRIV is made in a human cell line and has the same building blocks as the natural enzyme, and Elelyso is made in carrot cells and differs from the natural enzyme by 2 building blocks at one end and up to 7 at the other, according to their labels.

The rivals arrived during a crisis. In June 2009 a virus contaminated the bioreactors at Genzyme's plant in Allston, Massachusetts, and the resulting Cerezyme shortage opened the door for rival enzymes, with velaglucerase approved first (Deegan and Cox, 2012). Both labels now describe switching from imiglucerase at the same units per kilogram; VPRIV's says the first dose can come 2 weeks after the last Cerezyme infusion. Miglustat, the older pill, is the one Gaucher medicine with true generics, and CMS's 2024 figures put the generic at about $123 a capsule against $188 for brand-name Zavesca.

Cerezyme Long-Term Effects After 3 Decades of Infusions

Allergic reactions are the main long-term risk on Cerezyme's label, and they can appear years into treatment. A boxed warning, shared by the Gaucher enzymes, says life-threatening reactions including anaphylaxis have happened both early and after long use, which is why infusions start in a clinic with emergency equipment. About 15% of patients tested develop IgG antibodies to Cerezyme in the first year, mostly within 6 months and rarely after 12, and about 46% of those with antibodies had allergy-type symptoms. The other side effects the label lists include back pain, chills, dizziness, fatigue, headache, nausea, fever and vomiting.

Pregnancy is better studied than most families expect. Data from more than 500 pregnancies in the Gaucher registry, reports and published studies have not identified a drug-related risk of major birth defects or miscarriage, the label says, while untreated Gaucher disease can bring bleeding and organ complications during pregnancy. That registry, run since 1991 and supported by Sanofi, lists 317 sites worldwide, 86 of them in the US, on ClinicalTrials.gov, and Sanofi says the January 2026 extension of Cerezyme's label to the body-wide symptoms of type 3 was based on real-world evidence from that registry (Sanofi, 2026).

Infusions take 1 to 2 hours, usually every 2 weeks with no end date, and they do not have to happen in a hospital forever. Sanofi says Cerezyme can be given in a doctor's office, a treatment center or, in some cases, at home, once a care team decides that is safe. The first infusions still have to happen in a healthcare setting, under the label.

Why Gaucher Infusions Cannot Treat the Brain in Type 3

Enzyme infusions do not reach the brain, so they cannot treat the neurological side of type 3 Gaucher disease. Cerezyme's own label limits its use to non-central nervous system symptoms, and Sanofi says no approved treatment targets the neurological problems of type 3, which include poor balance and coordination, called ataxia, and trouble with memory and thinking. The blood-brain barrier, a lining that keeps most large molecules in the bloodstream out of the brain, stops an enzyme the size of imiglucerase.

Small pills can cross that barrier, which is why the field has tried them before. In a 2008 trial led by researchers at the National Institutes of Health, 21 of 30 people with type 3 were randomly assigned to add miglustat to their infusions, and after a year there was no significant difference between the groups in eye movements or in the other neurological and thinking tests (Schiffmann et al., 2008). Venglustat is a newer pill in the same family, designed by Sanofi to cross into the brain.

Venglustat and the LEAP2MONO Trial, a Pill Tested Head to Head Against Cerezyme

In the LEAP2MONO trial, venglustat beat Cerezyme on a combined score of balance and thinking after 52 weeks in people with type 3 Gaucher disease, while keeping spleen, liver and hemoglobin results about as stable as the infusions did (Sanofi, February 2026). The trial enrolled 43 people aged 12 and older who had been on enzyme infusions for at least 3 years and had reached their treatment goals, and it took them off real infusions in one of its 2 groups.

The brain results came from 2 tests. One rates ataxia, the trouble with balance, walking and coordination, using a modified version of a scale called SARA. The other, RBANS, scores memory, attention and language. On the 2 together, venglustat came out ahead of Cerezyme, with about a 2 in 100 chance of seeing a gap that size if the treatments were really equal (p = 0.0179). Sanofi says venglustat met 3 of 4 key secondary goals and performed as well as the infusions on spleen volume, liver volume and hemoglobin. Platelet count was also a key secondary goal, and Sanofi's announcements do not report its result.

“...no approved targeted treatments that specifically address the neurological symptoms of GD3.”

Sanofi, May 28, 2026

Venglustat was well tolerated overall with no new safety signals, Sanofi says. Headache affected 14.3% of the venglustat group against 18.2% on Cerezyme, and nausea, an enlarged spleen and diarrhea each affected 14.3% on venglustat, against 4.5%, 0 and 0 on Cerezyme. With 21 people in the venglustat group, 14.3% means 3 people. Venglustat has not worked everywhere it has been tried: in a separate Phase 3 trial in Fabry disease, called PERIDOT, pain fell in both groups and venglustat did not beat placebo on its main goal, while a second Fabry trial, CARAT, is still running (Sanofi, February 2026).

What the FDA is deciding about venglustat by November 25th

Sanofi announced on May 28, 2026 that the FDA had accepted its application for venglustat in type 3 Gaucher disease with priority review and a target action date of November 25, 2026, after granting it Breakthrough Therapy designation in March. The FDA can act before or after a target date. If it is approved, Sanofi says it would be the first treatment in the US for the neurological symptoms of type 3. The trial data cover people 12 and older who were already stable on infusions, followed for a year without anyone knowing their treatment, with a longer open-label phase still running, so children under 12 and people who have never had enzyme infusions were not part of the evidence. Venglustat is also under review in the European Union.

Cerdelga and the CYP2D6 Gene Test That Comes Before the Gaucher Pill

Cerdelga, the main pill for type 1 Gaucher disease, requires a gene test first, because a liver enzyme called CYP2D6 decides how fast the body clears it. The label covers adults whose test shows they are extensive, intermediate or poor metabolizers; the first 2 groups take 84 mg twice a day and poor metabolizers take 84 mg once a day. Ultra-rapid metabolizers may not reach a level that works, and people whose type cannot be determined have no recommended dose.

Other medicines matter as much as the gene. The label rules Cerdelga out for some combinations of CYP2D6 and CYP3A blockers and for some degrees of liver disease, because high blood levels can change the heart's electrical rhythm, and it advises against grapefruit and against use in people with certain heart conditions. The capsules are swallowed whole. Medicare paid for 142 Cerdelga patients in 2024, at an average of 533 capsules a year each, or about 1.5 a day.

Gaucher Disease Clinical Trials Open in 2026, and How Few Have US Sites

Of the 8 open or soon-to-open treatment trials that list Gaucher disease on ClinicalTrials.gov, 2 have a site in the United States, by Trial Friend's count of the registry on October 16, 2026, and the only US one that takes type 3 treats babies before birth. The bigger of the 2 tests FLT201, a one-time gene therapy from Spur Therapeutics, in a Phase 3 study of 45 adults with type 1 who have been stable on infusions or pills for at least 2 years; 15 of its 32 sites are in the US, and it excludes types 2 and 3 (NCT07223944). Its primary completion date is estimated for July 2028. The other, PEARL at the University of California, San Francisco, gives enzyme therapy in the womb to fetuses diagnosed with 1 of 8 storage diseases, Gaucher types 2 and 3 among them (NCT04532047).

For a child or adult in the US already living with type 3, that leaves the venglustat decision as the nearest new option, with nizubaglustat's Phase 2 trial the next pill to watch once it opens. Joining the Gaucher registry through a treating center is a way to add to the evidence in the meantime.

Questions Gaucher Families Search About Cerezyme, Costs and Venglustat

The first Gaucher enzyme was proved in a trial of 12 people, paid for largely by the NIH and a roughly $3 million donation from the National Gaucher Foundation (Deegan and Cox, 2012). In 2026 the newest Gaucher pill rests on a trial of 43. Rare disease evidence still comes from small groups of families who agree to be counted, and the November 25th decision will show what 43 of them can change for type 3.